At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NRXP NRX Pharmaceuticals Inc.
Market Closed 05-10 16:00:00 EDT
3.04
+0.11
+3.75%
盘后3.03
-0.01-0.33%
19:59 EDT
High3.19
Low2.90
Vol361.17K
Open2.93
D1 Closing2.93
Amplitude9.90%
Mkt Cap31.68M
Tradable Cap23.07M
Total Shares10.42M
T/O1.11M
T/O Rate4.76%
Tradable Shares7.59M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
NRX Pharmaceuticals Inc expected to post a loss of 55 cents a share - Earnings Preview
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression. The company has a partnership with Alvogen and Lotus to develop and commercialize NRX-101 for the suicidal bipolar depression treatment, as well as an agreement with Nephron Pharmaceuticals, Inc. to develop ketamine. The company was founded in 2015 and is based in Wilmington, Delaware.